The U.S. draft guidance regarding population and individual bioequivalence approaches: comments by a research‐based pharmaceutical company
2000
Generally, the motivation for switching from average bioequivalence to population and/or individual bioequivalence is well recognized in the light of certain limitations of the concept of average bioequivalence. However, this switch still results in unresolved issues which should be addressed before the regulatory guidance is finalized.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
23
References
13
Citations
NaN
KQI